Crestline Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Crestline Management’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	-$82K	–	291
2022 Q1	$82K	Buy	+1	New	+$153K	0.01%	255

Other funds holding TNXP

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crestline Management's TNXP Position: Q2 2022 in Review

Crestline Management sold out of Tonix Pharmaceuticals (TNXP) in Q2 2022, closing a stake of 1 share — an estimated $82K sold.

Crestline Management first reported a position in TNXP in Q1 2022 and held it in 1 quarter. The position peaked at $82K in Q1 2022. 23 funds tracked by Wall St. Rank hold TNXP as of Q2 2022.

Crestline Management reported no remaining Tonix Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Crestline Management sold 1 Tonix Pharmaceuticals share in Q2 2022, an estimated $82K.
Crestline Management first reported a position in Tonix Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Crestline Management's Tonix Pharmaceuticals position peaked at $82K in Q1 2022.
23 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2022.

Based on Crestline Management's 13F filing for Q2 2022, filed 12 Aug 2022.